News at MEDICA: ALPCO Announces the Launch of Several New Products in 2009
ALPCO will return to MEDICA, showcasing these new immunoassay kits, which cement the company's perennial committment to serving the demands of the pre-clinical research market. This will be ALPCO's fourth year at MEDICA as part of the “Best of New England” consortium of companies, located in the US pavilion in Halle 3, D15-4.
Dusseldorf, Germany, November 16, 2009 --(PR.com)-- ALPCO has unveiled several new ELISA kits this year. As the interest in animal models of insulin sensitivity in obese and pre-diabetic conditions continues to grow, ALPCO remains committed to serving the unique demands of this market with features including small sample volumes, reproducibility, robustness, and easy to follow protocols requiring minimal hands-on time.
In August, a collaborative effort with Sekisui Medical Corporation of Japan yielded the much anticipated launch of a Mouse HMW (high-molecular-weight ) and Total Adiponectin ELISA. First described in a correspondence from Dr. Hiroyuki Ebinuma (Tsukuba Research Institute) in the journal Clinica Chimica Acta in February 2009, this ELISA follows in the same vein as the often cited human Multimeric Adiponectin ELISA from ALPCO and Sekisui. That is, the new mouse-specific kit utilizes a similar system for simultaneous detection of both high-molecular-weight (HMW) and total adiponectin in sample sizes between 5 and 10 µl. Learn more at a website dedicated to this promising new research tool: www.adiponectinELISA.com/mouse.
Recently, ALPCO marked the commercial release of a pair of new assay kits: the Mouse Proinsulin ELISA and a complementary Rat Proinsulin ELISA. These two ELISA kits, the first commercially available rodent proinsulin ELISA kits, were described in abstracts presented at the Midwest Islet Club and Endocrine Society Annual Meetings. Both of these kits feature low sample volume, as well as high sensitivity and specificity. Because proinsulin is elevated in non-insulin dependent diabetes mellitus and the PI-to-insulin ratio is an early marker of overall β-cell dysfunction, these kits meet a pressing need in pre-clinical research laboratories studying early stages of type II diabetes and beta cell dysfunction.
Marking a turning point in GLP-1 ELISA technology, a second collaborative effort between ALPCO and Epitope Diagnostics of San Diego answers the need for reproducible, highly sensitive assays to measure both active (7-36) GLP-1 and combined (7-36 and 9-36) GLP-1 fragments. GLP-1, an incretin hormone, has been a focus of the diabetes & obesity research community recently. The first incretin therapy was approved by the FDA in 2006, and as more incretin-based drugs proceed through the clinical development process, the area of research that focuses on elucidating the physiological impact of incretin hormones has taken on greater significance. These efforts have been hampered by a lack of good tools, particularly when considering sensitivity. The GLP-1 (Active 7-36) assay is sensitive to 0.2 pmol/l, allowing researchers to discern low baseline values. Additionally, both kits demonstrate a marked stimulation index for fed versus fasted samples, a capability that has been lacking for commercial kits previously available to researchers.
ALPCO Immunoassays was founded in 1990 as an importer and distributor of high quality research immunoassay kits. The company's goals then, as now, have been to offer a diverse line of assays that appeal to its broad customer base while providing exceptional customer service and product support. In recent years, ALPCO has solidified its place in the market not only as a distributor but as a developer and manufacturer of immunoassays as well. ALPCO is returning to MEDICA for its fourth year as part of the “Best of New England” Consortium of companies, located in the US pavilion in Halle 3, D15-4.
###
In August, a collaborative effort with Sekisui Medical Corporation of Japan yielded the much anticipated launch of a Mouse HMW (high-molecular-weight ) and Total Adiponectin ELISA. First described in a correspondence from Dr. Hiroyuki Ebinuma (Tsukuba Research Institute) in the journal Clinica Chimica Acta in February 2009, this ELISA follows in the same vein as the often cited human Multimeric Adiponectin ELISA from ALPCO and Sekisui. That is, the new mouse-specific kit utilizes a similar system for simultaneous detection of both high-molecular-weight (HMW) and total adiponectin in sample sizes between 5 and 10 µl. Learn more at a website dedicated to this promising new research tool: www.adiponectinELISA.com/mouse.
Recently, ALPCO marked the commercial release of a pair of new assay kits: the Mouse Proinsulin ELISA and a complementary Rat Proinsulin ELISA. These two ELISA kits, the first commercially available rodent proinsulin ELISA kits, were described in abstracts presented at the Midwest Islet Club and Endocrine Society Annual Meetings. Both of these kits feature low sample volume, as well as high sensitivity and specificity. Because proinsulin is elevated in non-insulin dependent diabetes mellitus and the PI-to-insulin ratio is an early marker of overall β-cell dysfunction, these kits meet a pressing need in pre-clinical research laboratories studying early stages of type II diabetes and beta cell dysfunction.
Marking a turning point in GLP-1 ELISA technology, a second collaborative effort between ALPCO and Epitope Diagnostics of San Diego answers the need for reproducible, highly sensitive assays to measure both active (7-36) GLP-1 and combined (7-36 and 9-36) GLP-1 fragments. GLP-1, an incretin hormone, has been a focus of the diabetes & obesity research community recently. The first incretin therapy was approved by the FDA in 2006, and as more incretin-based drugs proceed through the clinical development process, the area of research that focuses on elucidating the physiological impact of incretin hormones has taken on greater significance. These efforts have been hampered by a lack of good tools, particularly when considering sensitivity. The GLP-1 (Active 7-36) assay is sensitive to 0.2 pmol/l, allowing researchers to discern low baseline values. Additionally, both kits demonstrate a marked stimulation index for fed versus fasted samples, a capability that has been lacking for commercial kits previously available to researchers.
ALPCO Immunoassays was founded in 1990 as an importer and distributor of high quality research immunoassay kits. The company's goals then, as now, have been to offer a diverse line of assays that appeal to its broad customer base while providing exceptional customer service and product support. In recent years, ALPCO has solidified its place in the market not only as a distributor but as a developer and manufacturer of immunoassays as well. ALPCO is returning to MEDICA for its fourth year as part of the “Best of New England” Consortium of companies, located in the US pavilion in Halle 3, D15-4.
###
Contact
ALPCO Diagnostics
Kate Kaplan
1-603-893-8914 x220
www.alpco.com
Kate Kaplan
1-603-893-8914 x220
www.alpco.com
Contact
Categories